11
Participants
Start Date
May 8, 2017
Primary Completion Date
August 19, 2022
Study Completion Date
October 3, 2025
Laboratory Biomarker Analysis
Correlative studies
Pharmacological Study
Correlative studies
Quality-of-Life Assessment
Ancillary studies
Ropidoxuridine
Given PO
Whole-Brain Radiotherapy
Undergo WBRT
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Fox Chase Cancer Center, Philadelphia
University of Maryland/Greenebaum Cancer Center, Baltimore
University of Michigan Comprehensive Cancer Center, Ann Arbor
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
University of Nebraska Medical Center, Omaha
UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ben Taub General Hospital, Houston
Huntsman Cancer Institute/University of Utah, Salt Lake City
UC San Diego Moores Cancer Center, La Jolla
University of California Davis Comprehensive Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH